Peptide Society Research Library
Retatrutide GLP-3 Research Guide
Retatrutide, also identified in scientific literature as LY3437943, is an investigational peptide engineered to activate the glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor, and glucagon receptor.
This guide examines retatrutide’s scientific background, molecular design, three-receptor mechanism, preclinical development, published clinical research, analytical testing considerations, and current regulatory status.
The information is provided for scientific education only. It does not provide medical advice, treatment recommendations, administration instructions, reconstitution directions, or dosage information.
Current regulatory notice: Retatrutide remains an investigational compound. It should not be described as an FDA-approved medication or as an approved treatment for obesity, diabetes, liver disease, or any other condition. Clinical-trial results do not establish that independently marketed materials are authentic, sterile, safe, or suitable for human use.
1. Retatrutide Research Overview
Retatrutide is a single peptide molecule designed to act as an agonist at three metabolically important receptors: the GIP receptor, GLP-1 receptor, and glucagon receptor. Because it engages all three receptor systems, researchers commonly describe it as a triple-receptor agonist or triple-hormone-receptor agonist.
Scientists are investigating whether one molecule that activates all three pathways can produce an integrated metabolic response that differs from the response produced by a single GLP-1 receptor agonist or a dual GIP and GLP-1 receptor agonist.
The three receptor systems are related but not interchangeable. GLP-1, GIP, and glucagon participate in nutrient sensing, pancreatic signaling, appetite regulation, gastrointestinal physiology, hepatic metabolism, and energy balance. The scientific interest in retatrutide comes from the deliberate combination of these signals within one engineered molecule.
Single engineered peptide
Retatrutide is not a mixture of three separate peptides. It is one molecule designed to activate three receptor types.
Investigational status
Published studies and Phase 3 announcements do not mean that the compound has received regulatory approval.
Metabolic research focus
Research has examined body weight, glycemic measures, liver fat, appetite-related effects, energy regulation, and safety outcomes.
No personal-use guidance
This page intentionally excludes dosing, injection, reconstitution, cycling, and treatment instructions.
2. Retatrutide Quick Facts
| Primary name | Retatrutide |
|---|---|
| Development identifier | LY3437943 |
| Research classification | Unimolecular GIP, GLP-1, and glucagon receptor agonist |
| Common informal term | GLP-3 or triple agonist |
| Primary receptor targets | GIPR, GLP-1R, and GCGR |
| Molecule type | Engineered peptide |
| Published research areas | Obesity, type 2 diabetes, metabolic physiology, body composition, liver fat, pharmacokinetics, and safety |
| Regulatory status | Investigational; not FDA approved as of July 2026 |
| Clinical developer | Eli Lilly and Company |
| Approved personal-use instructions | None |
The term “research compound” does not itself establish the identity, purity, sterility, or legal status of a material. Those questions require appropriate documentation, validated analytical methods, and compliance with applicable law.
Return to top3. What Does GLP-3 Mean?
“GLP-3” is an informal shorthand frequently used in online discussions and product naming. It refers to the compound’s activity across three receptor systems. It does not mean that retatrutide activates a scientifically recognized receptor called the GLP-3 receptor.
A more scientifically accurate description is: GIP, GLP-1, and glucagon receptor agonist. The description “triple agonist” is also appropriate when accompanied by an explanation of the three targets.
Clear terminology matters because “GLP-3” could otherwise create the impression that retatrutide belongs to a newly approved class or targets a separate naturally occurring hormone. Scientific writing should identify the individual receptors rather than relying entirely on the nickname.
4. History of Retatrutide and Multi-Receptor Research
Retatrutide emerged from a broader history of incretin and metabolic hormone research. Scientists first established that gastrointestinal hormones help coordinate the body’s response to nutrients. Two central hormones in this field are GIP and GLP-1, both of which can influence glucose-dependent insulin secretion.
Pharmacologic research initially focused on activating individual pathways, especially the GLP-1 receptor. The development of longer-acting GLP-1 receptor agonists demonstrated that peptide engineering could extend biological activity and make an otherwise short-lived hormone signal more suitable for controlled clinical investigation.
The next major concept was dual agonism. Rather than targeting GLP-1 alone, researchers designed single molecules capable of activating both GIP and GLP-1 receptors. This raised a broader scientific question: could carefully balanced activity at additional metabolic receptors create an even more comprehensive response?
Glucagon receptor signaling became an important part of that question. Glucagon is traditionally associated with hepatic glucose production, but its physiology also intersects with amino-acid metabolism, lipid handling, and energy expenditure. Researchers therefore explored whether glucagon receptor activity could complement incretin-receptor activity when incorporated into a deliberately balanced molecule.
Retatrutide represents this triple-agonist strategy. Early investigations evaluated its pharmacology and tolerability, followed by Phase 2 studies in adults with obesity and in participants with type 2 diabetes. Additional research examined liver-fat changes. The development program subsequently advanced into Phase 3 trials.
Preliminary Phase 3 results have been announced by the developer, but press-release results and conference announcements should be distinguished from a complete peer-reviewed publication. Full analysis requires study protocols, statistical methods, participant characteristics, adverse event data, missing-data handling, and complete results.
Return to top5. Molecular Design and Structural Research
Retatrutide is described as a unimolecular triple agonist. “Unimolecular” means the three receptor activities are incorporated into one engineered peptide rather than delivered through three separate compounds.
Designing a multi-receptor agonist involves more than joining hormone fragments together. Researchers must balance receptor potency, selectivity, stability, pharmacokinetics, and tolerability. Excessive or insufficient activity at one receptor may alter the overall biological response.
Sequence engineering
The amino-acid sequence is engineered to preserve interactions needed for activation of three related class B G-protein-coupled receptors. Although these receptors share structural features, each has distinct binding-pocket characteristics and extracellular conformations.
Receptor-binding conformation
Structural studies using cryogenic electron microscopy have examined retatrutide bound to GLP-1R, GIPR, and GCGR. These studies indicate that the peptide uses a combination of conserved interactions and receptor-specific conformations to activate the three targets.
This structural research helps explain how one peptide can recognize multiple receptors without behaving identically at each receptor. Receptor activation depends on the peptide’s orientation, contacts with extracellular receptor regions, and interactions within the transmembrane binding pocket.
Extended activity
Investigational peptide drugs may incorporate molecular modifications intended to reduce rapid degradation, promote reversible protein association, or extend circulation time. These design strategies must be evaluated empirically; the presence of a long-acting design feature does not by itself establish exact potency, stability, or shelf life for an independently manufactured material.
6. Proposed Mechanism of Action
Retatrutide’s mechanism is based on agonism of three class B G-protein-coupled receptors. Activating these receptors can stimulate intracellular signaling pathways, including cyclic AMP-related signaling, but the resulting physiologic effect depends on receptor distribution, tissue type, nutrient state, dose exposure, and the relative balance of receptor activity.
The mechanism should therefore not be reduced to a single claim such as “increases metabolism.” Retatrutide is being studied as a coordinated signaling molecule whose effects may involve the central nervous system, pancreas, gastrointestinal tract, liver, adipose tissue, and other metabolically active tissues.
7. GLP-1 Receptor Activity
GLP-1 is an incretin hormone released in response to nutrient intake. GLP-1 receptor signaling has been investigated extensively in relation to glucose-dependent insulin secretion, glucagon regulation, appetite, satiety, gastric motility, and post-meal glucose handling.
Pancreatic signaling
Under glucose-responsive conditions, GLP-1 receptor activation can support insulin secretion from pancreatic beta cells. The glucose-dependent nature of this pathway is important because the signal is influenced by the surrounding metabolic environment.
Appetite and satiety pathways
GLP-1 receptor signaling can influence neural pathways involved in appetite and meal termination. In clinical research, changes in energy intake may contribute to body-weight outcomes, although appetite is complex and cannot be attributed to one receptor alone.
Gastrointestinal effects
GLP-1 receptor agonism may delay gastric emptying, particularly during early exposure. Gastric-emptying effects may change over time and can vary according to the specific molecule, exposure pattern, meal type, and study method.
Gastrointestinal symptoms have also been commonly observed in research involving incretin-based agonists. Any discussion of beneficial study outcomes should be accompanied by an accurate discussion of tolerability and discontinuation.
8. GIP Receptor Activity
GIP, historically called glucose-dependent insulinotropic polypeptide, is another incretin hormone released after nutrient ingestion. GIP receptor signaling participates in glucose-dependent insulin secretion and has complex effects across adipose tissue, the nervous system, bone, and other tissues.
The role of GIP receptor agonism in multi-receptor therapies has generated substantial scientific interest. Earlier assumptions that GIP signaling would be undesirable in metabolic research have been reconsidered as researchers gained a more detailed understanding of receptor pharmacology and combined agonism.
In a triple agonist, GIP receptor activity may interact with GLP-1 and glucagon receptor signaling rather than acting in isolation. The overall outcome depends on the molecule’s relative receptor potency and the tissues exposed to the signal.
9. Glucagon Receptor Activity
Glucagon is produced primarily by pancreatic alpha cells and is commonly associated with maintaining glucose availability during fasting. Glucagon receptor activation in the liver can promote hepatic glucose output, which is one reason glucagon activity must be carefully balanced in a metabolic agonist.
Glucagon physiology extends beyond glucose production. Research has connected glucagon signaling with amino-acid metabolism, lipid metabolism, hepatic function, and energy expenditure. These broader actions helped motivate the inclusion of glucagon receptor agonism in multi-receptor peptide design.
In retatrutide, the accompanying incretin-receptor activities are hypothesized to offset or modify some glucose-related effects while allowing investigation of glucagon-associated energy and liver metabolism. This remains a question of pharmacologic balance rather than a guarantee of a particular outcome.
10. How Triple-Receptor Agonism May Work Together
The central research concept behind retatrutide is that the three pathways may be complementary:
- GLP-1 receptor activity may influence appetite, gastric physiology, insulin secretion, and post-meal metabolic responses.
- GIP receptor activity may contribute to glucose-responsive pancreatic signaling and modify metabolic and neural responses.
- Glucagon receptor activity may affect hepatic metabolism, substrate utilization, and energy expenditure.
A triple agonist does not merely produce the mathematical sum of three separate effects. Receptor pathways interact, and the activation of one pathway may alter the consequences of another. Researchers study this interaction through receptor assays, animal models, metabolic measurements, imaging, clinical biomarkers, and controlled trials.
Relative receptor activity is critical. A molecule with a different balance of GLP-1R, GIPR, and GCGR agonism could produce a different efficacy, safety, or tolerability profile even if it is also described as a triple agonist.
11. Preclinical and Laboratory Research
Preclinical development typically includes receptor-binding studies, functional signaling assays, cellular models, pharmacokinetic experiments, and animal studies. These stages help researchers determine whether a candidate has sufficient activity and an acceptable profile to justify clinical investigation.
Receptor assays
Cell-based assays can measure whether retatrutide activates each target receptor and can compare its signaling profile with reference agonists. Results may be expressed through potency, maximal response, or other pharmacologic measures.
Animal metabolic models
Animal studies may examine food intake, body weight, glucose-related biomarkers, lipid metabolism, energy expenditure, and changes in tissue composition. These studies can establish proof of concept, but animal findings cannot be assumed to predict the magnitude or safety of effects in humans.
Pharmacokinetic analysis
Researchers evaluate absorption, exposure, distribution, metabolism, and elimination. Pharmacokinetic measurements help determine whether the intended molecular modifications produce sustained and reproducible exposure.
Translation limitations
Differences in receptor expression, metabolism, body size, diet, physiology, and experimental design limit direct translation from animal models to humans. Preclinical findings are best understood as evidence supporting further investigation rather than proof of clinical benefit.
12. Published Clinical Research
Phase 2 obesity trial
A randomized, double-blind, placebo-controlled Phase 2 trial evaluated retatrutide in adults with obesity or overweight plus at least one weight-related condition. The study examined multiple dose groups over 48 weeks.
Published results reported dose-dependent reductions in body weight. The study also documented adverse events, with gastrointestinal events among the commonly reported tolerability findings. The authors concluded that the results supported additional Phase 3 evaluation.
These results apply to the defined trial population, protocol, dose escalation schedules, clinical material, and monitoring procedures. They do not establish the safety or identity of products sold outside the authorized clinical-development program.
Phase 2 type 2 diabetes trial
A separate Phase 2 investigation studied retatrutide in participants with type 2 diabetes. Researchers evaluated glycemic measures, body-weight changes, safety, tolerability, and dose selection for later development.
The study reported changes in glycated hemoglobin and body weight, while also documenting adverse events and discontinuations. Interpretation requires attention to baseline characteristics, comparator groups, concomitant medications, study duration, and statistical methods.
Phase 3 development
The retatrutide development program advanced into multiple Phase 3 studies examining populations with obesity, overweight, cardiovascular disease, type 2 diabetes, obstructive sleep apnea, osteoarthritis, and other obesity-associated conditions.
In December 2025, Lilly announced preliminary results from the TRIUMPH-4 trial involving participants with obesity and knee osteoarthritis. In May 2026, the company announced preliminary results from the pivotal TRIUMPH-1 obesity study. These announcements indicate progress in the clinical program but do not equal regulatory approval.
How to read preliminary Phase 3 announcements: Top-line announcements are useful, but complete evaluation should wait for peer-reviewed or fully presented data describing the protocol, estimand, participant disposition, adverse events, discontinuations, missing-data assumptions, and subgroup analyses.
13. Retatrutide and Liver-Fat Research
A substudy of the Phase 2 obesity trial investigated liver-fat changes among participants with elevated liver fat consistent with metabolic dysfunction-associated steatotic liver disease research criteria.
Researchers used imaging-based measurements to evaluate relative changes in liver fat over time. The study reported reductions in liver-fat content in several retatrutide groups.
Liver-fat reduction is a research outcome and should not be equated with an approved treatment claim. Metabolic liver disease includes multiple dimensions, including inflammation, cellular injury, fibrosis, cardiometabolic risk, and long-term clinical outcomes. A change in imaging-measured fat does not by itself establish improvement in all aspects of liver disease.
14. Retatrutide Compared With Related Compounds
| Compound or class | Primary receptor targets | Main research distinction |
|---|---|---|
| Retatrutide | GIPR, GLP-1R, and GCGR | Single-molecule triple-receptor agonism |
| Tirzepatide | GIPR and GLP-1R | Dual incretin-receptor agonism |
| Semaglutide | GLP-1R | Selective GLP-1 receptor agonism |
| Glucagon agonist research | GCGR | Focuses more directly on glucagon-mediated hepatic and energy pathways |
| Amylin-based compounds | Amylin-receptor pathways | Use a different hormonal system involved in satiety and meal regulation |
Retatrutide vs. tirzepatide
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity. This makes retatrutide pharmacologically distinct, but it does not mean that all differences in trial results can be attributed solely to the third receptor.
Reliable comparison requires a direct randomized head-to-head study with comparable participants, protocols, durations, adherence, statistical methods, and outcome definitions. Comparing percentages from unrelated trials can be misleading.
Retatrutide vs. semaglutide
Semaglutide primarily targets GLP-1R, while retatrutide targets GLP-1R, GIPR, and GCGR. Their molecular structures, receptor profiles, approved status, clinical evidence, and safety datasets are different.
Retatrutide vs. “GLP-1 peptides” generally
“GLP-1 peptide” is a broad phrase that may include different molecules with different sequences, pharmacokinetics, formulations, indications, and regulatory statuses. Receptor category alone is not enough to establish interchangeability.
Retatrutide vs. cagrilintide
Cagrilintide is an amylin analogue and does not share retatrutide’s triple-receptor mechanism. Research combining amylin and GLP-1 pathways represents a different strategy from integrating GIP, GLP-1, and glucagon receptor agonism in one molecule.
15. Pharmacology and Pharmacokinetic Considerations
Receptor potency
Receptor potency describes the concentration of a compound required to produce a specified response in a particular experimental system. Potency values can vary with cell type, receptor density, assay design, signal measured, incubation time, and reference standard.
Pharmacodynamics
Pharmacodynamics refers to what a compound does to a biological system. For retatrutide, pharmacodynamic measures may include changes in glucose biomarkers, appetite-related measures, gastric emptying, body weight, lipid markers, liver fat, and other metabolic endpoints.
Pharmacokinetics
Pharmacokinetics describes how a compound is absorbed, distributed, metabolized, and eliminated. Clinical-development material is manufactured and characterized under controlled conditions. Its pharmacokinetic findings cannot automatically be applied to independently manufactured substances carrying the same name.
Immunogenicity
As with other peptide-based investigational drugs, researchers may assess anti-drug antibodies and determine whether they affect exposure, pharmacologic response, or adverse events. Immunogenicity can be influenced by sequence, impurities, aggregation, formulation, manufacturing conditions, and individual biology.
16. General Peptide Manufacturing Principles
Peptide manufacturing commonly involves controlled synthesis, purification, identity confirmation, concentration or content determination, formulation, and stability assessment. The exact process used for a proprietary clinical compound may not be publicly available in full detail.
Peptide synthesis
Many engineered peptides are produced through solid-phase peptide synthesis or related methods. Protected amino acids are added in a controlled sequence, followed by cleavage and deprotection.
Purification
Crude synthesis material may contain deletion sequences, truncated peptides, residual reagents, stereochemical impurities, and other process-related substances. Chromatographic purification is used to separate the target molecule from impurities.
Formulation and lyophilization
Lyophilization removes water under controlled low-temperature and vacuum conditions. The appearance of a lyophilized material does not verify its identity, purity, sterility, content, or stability.
Manufacturing consistency
Lot-to-lot consistency requires validated methods, controlled raw materials, in-process testing, release specifications, environmental controls, and stability monitoring. A label claim alone cannot establish that these requirements were met.
17. Analytical Testing and Quality Documentation
A scientifically meaningful evaluation should consider multiple analytical attributes. One purity number is not a complete quality assessment.
| Test or document | What it may help evaluate | What it does not prove by itself |
|---|---|---|
| HPLC or UPLC | Chromatographic purity and related peaks | Definitive molecular identity or sterility |
| Mass spectrometry | Molecular mass and identity-related evidence | Complete purity, potency, or biological activity |
| Peptide content assay | Quantity of peptide present | Absence of contaminants |
| Water-content analysis | Residual moisture | Molecular identity |
| Endotoxin testing | Level of bacterial endotoxins under the stated method | Overall sterility or suitability for administration |
| Sterility testing | Growth of specified microorganisms under test conditions | Long-term stability or absence of every contaminant |
| Residual solvent testing | Selected process solvents | Peptide identity or receptor activity |
| Certificate of Analysis | Summary of lot-specific test results | Accuracy unless methods and issuing laboratory are verified |
Understanding a purity claim
A claim such as “99% purity” commonly refers to chromatographic area purity under a particular method. It does not necessarily mean that 99% of the vial’s total mass is active peptide. Water, counterions, excipients, and non-UV-detectable substances may not be represented in the same way.
Lot-specific documentation
Quality documentation should identify the tested lot, laboratory, test date, methods, acceptance criteria, and results. A report for one lot should not be presented as proof for every future lot.
Identity versus purity
Identity and purity answer different questions. A chromatogram may show one dominant peak without definitively proving that the peak is retatrutide. Orthogonal testing, such as mass spectrometry and other identity methods, strengthens analytical confidence.
18. Laboratory Storage and Handling Principles
Storage conditions should be based on validated, lot-specific stability information. Generic internet instructions cannot substitute for a stability program.
- Protect laboratory peptide materials from uncontrolled heat.
- Minimize unnecessary light exposure when light sensitivity is possible.
- Prevent moisture intrusion into lyophilized material.
- Avoid repeated temperature cycling when not supported by stability data.
- Maintain chain-of-custody and lot identification.
- Use calibrated temperature-monitoring equipment.
- Document storage deviations and assess their effect scientifically.
This section does not provide reconstitution or administration instructions. The correct storage period after preparation depends on formulation, solvent, container, sterility controls, concentration, temperature, light exposure, and validated stability data.
19. Important Research Limitations
Investigational does not mean approved
Advancement into Phase 3 testing indicates that a compound is undergoing extensive research. It does not establish regulatory approval, commercial authorization, or suitability for use outside a trial.
Named material may not be authentic
A vial labeled “retatrutide” is not necessarily the same material used in Lilly-sponsored studies. Identity requires testing, and even correct molecular identity does not establish equivalent formulation, manufacturing quality, stability, sterility, or clinical performance.
Trial participants receive medical monitoring
Clinical trials use defined eligibility criteria, dose-escalation protocols, adverse-event monitoring, laboratory assessments, trained investigators, controlled supplies, and stopping rules. Research results should not be separated from these safeguards.
Long-term evidence remains developing
Longer-duration evidence is needed to understand durability, treatment discontinuation, weight regain, body composition, rare adverse events, cardiovascular outcomes, and effects in diverse populations.
Head-to-head claims require head-to-head evidence
It is not scientifically sound to declare one compound superior solely because separate trials reported different average outcomes. Direct randomized comparisons provide stronger evidence.
20. Frequently Asked Questions
What is retatrutide?
Retatrutide is an investigational peptide engineered to activate GIP, GLP-1, and glucagon receptors.
What is LY3437943?
LY3437943 is the development identifier used for retatrutide in scientific and clinical-trial materials.
Is retatrutide a GLP-1 receptor agonist?
It activates the GLP-1 receptor, but it also activates GIP and glucagon receptors. Describing it only as a GLP-1 agonist leaves out much of its intended pharmacology.
Is GLP-3 a real receptor?
No established “GLP-3 receptor” is responsible for retatrutide’s mechanism. GLP-3 is an informal nickname referring to three-receptor activity.
Why is retatrutide called a triple agonist?
It is designed to act as an agonist at three receptors: GIPR, GLP-1R, and GCGR.
Is retatrutide FDA approved?
No. As of July 2026, retatrutide remains investigational and should not be marketed or described as an FDA-approved medication.
Have Phase 3 results been announced?
Yes. Lilly announced preliminary results from Phase 3 studies, including TRIUMPH-4 in December 2025 and TRIUMPH-1 in May 2026. Preliminary announcements do not constitute regulatory approval.
Is retatrutide the same as tirzepatide?
No. Tirzepatide targets GIP and GLP-1 receptors. Retatrutide also includes glucagon receptor agonism.
Is retatrutide the same as semaglutide?
No. Semaglutide primarily targets GLP-1R, while retatrutide is designed to activate GLP-1R, GIPR, and GCGR.
What has retatrutide been studied for?
Published and ongoing research has examined obesity, overweight, type 2 diabetes, liver fat, metabolic physiology, osteoarthritis-related outcomes, cardiovascular risk populations, and other obesity-associated conditions.
Does retatrutide affect appetite?
Appetite-related pathways are among the proposed contributors to its clinical effects, particularly through incretin-receptor signaling. The complete response is likely to involve multiple tissues and pathways.
Why include glucagon receptor activity?
Researchers are investigating whether glucagon receptor activity can contribute to energy expenditure, substrate metabolism, and hepatic effects when balanced with GIP and GLP-1 receptor agonism.
Does a clinical trial prove independently sold material is safe?
No. Trial findings apply to the controlled investigational product, protocol, manufacturing system, storage conditions, and medical oversight used in that study.
Can appearance confirm retatrutide identity?
No. Many lyophilized materials look similar. Identity requires appropriate analytical testing.
Does 99% HPLC purity prove sterility?
No. Chromatographic purity and sterility are separate quality attributes assessed through different methods.
Does purity establish the amount of peptide in a vial?
Not necessarily. Chromatographic area purity does not automatically equal peptide content or total active mass.
What should a useful Certificate of Analysis include?
It should identify the lot, tests, methods, acceptance criteria, numerical results, dates, and issuing laboratory. The information should be traceable to the specific material being evaluated.
Why are both HPLC and mass spectrometry useful?
HPLC can evaluate chromatographic purity, while mass spectrometry provides molecular-mass evidence supporting identity. The methods answer different questions.
Can animal-study findings be applied directly to humans?
No. Animal studies are valuable for hypothesis testing but are limited by species differences, study design, exposure, and physiology.
Do preliminary press-release results equal peer-reviewed evidence?
No. Press releases provide selected top-line information. Full evaluation requires complete methods, data, and scientific review.
Can separate trials prove retatrutide works better than another drug?
Separate trials can generate hypotheses, but a randomized head-to-head study provides stronger comparative evidence.
Does this guide provide dosage information?
No. This guide is educational and intentionally excludes dosing, preparation, administration, and personal-use instructions.
Is this guide medical advice?
No. It is a scientific overview and is not a substitute for advice from a licensed healthcare professional.
21. Selected Scientific and Official References
References should be reviewed directly for complete methods, study populations, limitations, adverse-event findings, conflicts of interest, and statistical analysis.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. View study
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group Phase 2 trial. The Lancet. 2023. View PubMed record
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized Phase 2a trial. Nature Medicine. 2024. View study
- Li W, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR by retatrutide. Cell Discovery. 2024. View study
- ClinicalTrials.gov. A Study of Retatrutide in Participants With Obesity and Established Cardiovascular Disease. NCT05882045. View trial record
- ClinicalTrials.gov. A Study of Retatrutide Once Weekly in Participants With Obesity or Overweight. NCT05931367. View trial record
- Eli Lilly and Company. What to Know About Retatrutide. View official information
- Eli Lilly and Company. TRIUMPH-4 preliminary Phase 3 results, announced December 11, 2025. View announcement
- Eli Lilly and Company. TRIUMPH-1 preliminary Phase 3 results, announced May 21, 2026. View announcement
Scientific references are included for educational transparency. Linking to a study does not imply that the study evaluated or endorsed any independently supplied product.
23. Research-Use and Medical Disclaimer
Retatrutide is an investigational compound and is not FDA approved. This page is provided solely for educational and scientific reference purposes.
Nothing on this page should be interpreted as medical advice, a diagnosis, a treatment recommendation, a statement of clinical suitability, or instructions for human or veterinary administration. This guide does not provide dosing, injection, preparation, reconstitution, cycling, or self-experimentation instructions.
Published clinical results apply to investigational material supplied and controlled within the applicable clinical-development program. They do not establish the identity, purity, sterility, safety, legal status, or clinical equivalence of independently marketed materials.
Researchers are responsible for complying with institutional rules, applicable laws, safety requirements, documentation standards, and appropriate laboratory practices.